The attention-getting articles about COVID-19 included news about Pfizer's booster and the FDA's rejection Zyesami (aviptadil) for treatment of COVID-19-related respiratory failure.
The FDA didn’t have enough data to assess the risks and benefits of Zyesami.
Regeneron also announced an expanded contract with the U.S. government for the purchase of additional doses of REGEN-COV.
The FDA had previously issued an EUA for those over the age of 65 and those at high risk for severe COVID-19 or exposure to the virus.
Some have expressed concerns about the risk of myocarditis and unknown longer-term side effects.
The dose is one-third of the dose given to people 12 years and older.